Illumina (ILMN) will release TruSight Oncology 500 v2, a new version of its flagship cancer research assay to enable comprehensive genomic profiling. The assay is currently under development, with global release planned for mid-2025. Detailed plans for the product will be shared November 21 in a spotlight presentation at the annual meeting of the Association of Molecular Pathology in Vancouver, British Columbia. TSO 500 v2 assesses hundreds of genes across all variant classes, and immuno-oncology biomarkers, in a single assay from one sample. At AMP, several abstracts accepted for poster presentations will demonstrate preliminary analytical performance data and automation compatibility of TSO 500 v2.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ILMN:
- Cantor sees six changes to Nasdaq 100 Index in December rebalance
- Nvidia initiated, Airbnb downgraded: Wall Street’s top analyst calls
- Illumina resumed with an Equal Weight at Morgan Stanley
- Illumina price target raised to $184 from $170 at Stephens
- Illumina price target lowered to $185 from $195 at Piper Sandler
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Historical%20Trades%20%7C%20Nasdaq&_biz_n=10&rnd=27119&cdn_o=a&_biz_z=1743328430750)
%20Summary%20%7C%20Nasdaq&_biz_n=12&rnd=929090&cdn_o=a&_biz_z=1743328430864)
